Heartscape Technologies
Stage
Acquired | AcquiredTotal Raised
$21.4M
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Heartscape Technologies Patents
Heartscape Technologies has filed 7 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/14/2008 | 1/5/2010 | Grant |
Application Date | 11/14/2008 |
|---|---|
Grant Date | 1/5/2010 |
Title | |
Related Topics | |
Status | Grant |
Heartscape Technologies Frequently Asked Questions (FAQ)
Where is Heartscape Technologies's headquarters?
Heartscape Technologies's headquarters is located at 9160 Rumsey Road, Columbia.
What is Heartscape Technologies's latest funding round?
Heartscape Technologies's latest funding round is Acquired.
How much did Heartscape Technologies raise?
Heartscape Technologies raised a total of $21.4M.
Who are the investors of Heartscape Technologies?
Investors of Heartscape Technologies include Roper Technologies, Radius Ventures, Delta Private Equity Partners, Investor Growth Capital and Scottish Equity Partners.
Who are Heartscape Technologies's competitors?
Competitors of Heartscape Technologies include JenaValve, Itamar Medical, SynCardia Systems, Soteira, Concentric Medical and 11 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Heartscape Technologies to Competitors
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation, and is proven to resolve and restore normal mitral valve function. It was formerly known as mValve. The company was founded in 2007 and is based in St. Louis Park, Minnesota.
JenaValve develops, manufactures, and markets transcatheter aortic valve implantation systems (TAVI) to treat patients suffering from aortic valve disease. The company's transapical aortic valve system is CE-marked and currently marketed in Europe and other markets worldwide. The company was founded in 2006 and is based in Irvine, California.
FocalCool is a medical device company. The company's goal is to develop technology that aims to reduce tissue damage from heart attacks and strokes. Using a special catheter system the company can apply rapid localized cooling to internal organs. The FocalCool team is made up of a Rowan University engineering professor, two engineers (one is a Rowan engineering graduate), and several Rowan engineering students.
Cardiac Power is a non-blood-contacting left ventricular assist device for the treatment of congestive heart failure
CardioKinetix develops a percutaneous treatment for patients with left ventricular dilation after an anterior myocardial infarction (MI). The implantable device, called the PARACHUTE is a partitioning membrane deployed within the compromised ventricle. The PARACHUTE partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, and decreases the overall volume. Options for patients whose ventricle has enlarged are limited, with most on medical therapy and/or a cardiac resynchronization device that only benefits heart failure patients with a specific EKG pattern.
Cardiola have designed a patented device, the m.pulse device designed to treat chronic heart failure (CHF), non-surgically, in a patient's home.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
